Leadership Expansion at ORIC Pharmaceuticals
ORIC Pharmaceuticals, Inc., a clinical stage oncology company, has taken a significant step forward with the recent appointment of Kevin Brodbeck, PhD, as its Chief Technical Officer (CTO). This strategic role reflects ORIC's commitment to advancing its clinical programs and addressing the challenges of therapeutic resistance in cancer.
Introducing Kevin Brodbeck
With over 25 years of experience, Dr. Brodbeck brings an impressive background in technical operations and quality assurance within the pharmaceutical industry. His expertise spans across chemistry, manufacturing, controls (CMC), and regulatory affairs, which positions him perfectly to lead ORIC into its next phase of development.
A Strong Track Record
Before joining ORIC, Dr. Brodbeck served as the Chief Technical and Development Operations Officer at Deciphera Pharmaceuticals. There, he played pivotal roles in various functions including Pharmaceutical Sciences and Clinical Operations. His experience at Deciphera was instrumental, especially during the strategic expansion of Qinlock internationally and preparing Romvimza for approval in different markets, showcasing his ability to lead complex projects to fruition.
Focus on Upcoming Clinical Trials
As ORIC prepares for potentially impactful Phase 3 trials for its lead candidates, ORIC-944 and enozertinib (ORIC-114), Dr. Brodbeck's leadership will be crucial. CEO Jacob M. Chacko noted, "As we approach the potential initiation of these trials, the roles of CMC and Technical Operations become increasingly critical." This appointment is not merely a leadership change; it symbolizes ORIC's readiness to elevate its operational capabilities as it moves deeper into late-stage development.
Driving Innovations in Cancer Therapy
Dr. Brodbeck's vision aligns with ORIC's mission to innovate cancer treatment. His excitement about joining the team underscores a mutual commitment to developing therapies that effectively combat cancer resistance, with the goal of enhancing patients' quality of life. "I'm thrilled to join ORIC as the company makes this pivotal transition into late-stage development," stated Dr. Brodbeck.
About ORIC Pharmaceuticals
ORIC Pharmaceuticals focuses on developing solutions for cancer treatment by addressing mechanisms that lead to treatment resistance. The company is actively advancing two primary candidates: ORIC-944, which inhibits the polycomb repressive complex 2 (PRC2), targeting prostate cancer, and enozertinib (ORIC-114), which aims to tackle various genetically defined tumors.
Commitment to Patients and Innovation
With offices located in South San Francisco and San Diego, California, ORIC is strategically positioned to drive innovation in cancer therapy development. The team's grow-and-drive strategy aligns with their mission to improve patient outcomes through advanced therapeutic solutions. Staying committed to overcoming resistance is at the core of ORIC’s philosophy.
Frequently Asked Questions
Who is Kevin Brodbeck?
Kevin Brodbeck is the newly appointed Chief Technical Officer of ORIC Pharmaceuticals, bringing over 25 years of experience in the pharmaceutical industry.
What is ORIC Pharmaceuticals focused on?
ORIC Pharmaceuticals is dedicated to developing oncology treatments aimed at overcoming resistance mechanisms in cancer therapies.
What are ORIC's main clinical candidates?
ORIC's lead clinical candidates include ORIC-944 and enozertinib (ORIC-114), targeting resistance in various cancers.
Why is the CTO role important for ORIC now?
The CTO role is critical as ORIC prepares for late-stage clinical trials for its lead products and enhances its operational capacity.
Where is ORIC Pharmaceuticals located?
ORIC Pharmaceuticals has its offices in South San Francisco and San Diego, California, allowing it to leverage local innovation hubs.
